The role of Wilms' tumor genes by Hirose, Masao
Etiology of WAGR syndrome
In 1964, Miller et al . reported an association of
Wilms’tumor with aniridia, hemihypertrophy and
other congenital malformations (1). A new disease
entity, WAGR syndrome consisting of Wilms’
tumor with aniridia, genitourinary malformations,
and mental retardation was subsequently proposed
(2). Wilms’tumor is the most common childhood
intraabdominal solid tumor of thekidney (3). Thereafter,
Riccardi et al . found a correlation between WAGR
syndrome and karyotypic abnormality within the
short arm of one copy of chromosome 11, at band
p13 (4). This constitutional chromosomal deletion
provided the first clue to the genetic events in the
development of Wilms’tumor.
In 1971, Knudson compared cases showing the
earlier age of onset and the bilateral presentation
of retinoblastomas (RB) in children with a family
history of this disease with those showing the uni-
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lateral tumors and proposed a model to explain the
etiology of this disease, the two-event hypothesis
(5). This model predicts that tumor formation depends
on two-rate limiting genetic events. Tumorigenesis
in children who have a constitutional lesion, either
inherited from a parent or resulting from a sponta-
neous mutation, needed only one new genetic event.
Contrary to this, sporadic cases required two inde-
pendent somatic mutations. A similar model for
Wilms’tumor was proposed later (6). Subsequent
genetic studies of a number of tumors confirmed
that the two postulated genetic events are caused
by the inactivation of both alleles of a tumor
suppressor gene (7). Now, that Wilms’tumor is
caused by the Wilms’tumor suppressor gene
WT1 is demonstrated. The Wilms’tumor gene re-
lated diseases are summarized in Table 1.
Structure and regulatory mechanisms of
WT1
The WT1 gene that is mapped to chromosome
locus 11p13 is encoded by 10 exons, resulting in
messenger RNA subject to a complex pattern of
alternative splicing (8, 9). The WT1 promoter has
three transcription initiation sites and the gene is a
member of the GC-rich, TATA-less and CCAAT-less
class of RNA polymerase II genes (10, 11). The
WT1 transcript is～3.5 kb long and encodes a
zinc-finger protein, WT1, with a predicted molecu-
lar weightMr of 47kd to 49kd, depending on the
presence or absence of two alternatively spliced
exons. The first alternative splicing introduces
exon 5, encoding 17 amino acids (+17aa), just
proximal to the first of four zinc fingers. The sec-
ond results in an insertion of three amino acids
(+KTS) between the third and fourth zinc fingers.
The most prevalent WT1 mRNA variant has both
of the insertions present (+KTS and +17aa), and
the least common form is missing both insertions
(-KTS and -17aa) (9). The insertion of three amino
acids (+KTS) disrupts the distance between zinc
fingers 3 and 4 and thus alters its DNA-binding
specificity (10). The four patterns of alternative
splicing are shown in Figure 1.
The elements responsible for regulating the tissue
specific expression of WT1 are not known, although
Sp1 and GATA-1 have been shown to positively
modulate WT1 expression (11-13). In addition, a
cell type-specific enhancer has been identified
within the 3’end of the human WT1 gene (14).
Recently, Pax 2 and Pax 8 were shown to contrib-
ute to the regulation of WT1. When Pax 2 and
Pax 8 expression becomes maximal, WT1 levels
begin increasing (15). Recently, it was reported that
the ectopic expression of p50 and p65 subunits of
NF-κB stimulated the murine WT1 promoter activity
by 10-30-fold in a transient transfection assay (16).
Subsequently, the regulators or signal cascades
that could modulate the function of WT1 were
studied. Evidence was obtained that WT1 protein
expressed exogenously in fibroblasts was phosphorylated
in vivo and that treatment with forskolin, which ac-
Table 1. Wilms’tumor genes and related diseases
Disease name Clinical manifestations Genetic abnormality
Incidence of
Wilms’tumor
WAGR synd. Aniridia, genitourinary malformations,
mental retardation, Wilms’tumor
Deletion at 11p13 (WT1) > 30 %
Denys-Drash synd. Intersexual disorders, nephropathy, Wilms’tumor WT1 point mutation > 90%
Beckwith-Wiedemann synd. Macroglossia, organomegaly, hemihypertrophy,
embryonal tumors
Duplication of paternal allele of
11p15 (WT2)
< 5 %
Figure１. The four patterns of alternative splicing of the WT1
gene. The details are explained in the text.
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tivates the cAMP-dependent protein kinase (PKA)
in vivo , induced phosphorylation of additional sites
at Ser-365 and Ser-393 in WT1, resulting in abol-
ishment of the DNA binding capacity of WT1 in
vitro (17). In addition, Maheswaran and coworkers
presented evidence that p53 physically inter-
acts with WT1 in transfected cells and that WT1
transcriptional activity might be modulated by p53
(18).
Whereas in NIH-3T3 cells wild type WT1 re-
pressed expression, its transfection into Saos-2 cells,
which lack endogenous p53, resulted in increased
transcription from a promoter into which epidermal
growth factor receptor 1 (EGR-1) consensus binding
sites had been added (18). However, the WT1
transcriptional activity was independent of p53
genotype in the induction of P3 promoter activity
of mouse insulin-like growth factor II gene (IGF-2)
in primary cultures derived from p53 wild type
(p53+/+) and knock-out (p53+/-) mouse embryo
(19). There is a report that upregulation of WT1
expression is associated with an expression marker
for the differentiation into monocytes/macrophages
of c-fms and Mac-1 in murine myeloblastic cell
line, M1, cells cultured in leukemia inhibitory factor
(LIF), resulting in apoptotic cell death (20).
Functions of WT1
The WT1 gene encodes a zinc finger transcrip-
tion factor, which binds to GC-rich sequences
(5’-GCGGGGGCG-3’) and functions as a transcriptional
activator or repressor (21). It represses trans-
cription of growth factor [platelet derived growth
factor-A (PDGF-A) chain, colony stimulating
factor-1 (CSF-1), and IGF-2] and growth factor
receptor (IGF-1R) genes, and the other genes
[retinoic acid receptor-alpha (RAR-α), c-myc, and
bcl-2](22-27). In addition, it’s been known that
WT1 mediates the expression of genes such as
EGR-1, EGF-R, inhibin-α, Pax2, transforming growth
factor-beta (TGF-β) and WT1 itself (28-33). The
transient transfection ofWT1 constructs into NIH-3T3
or 293 cells results in the transcriptional repres-
sion of a number of co-transfected promoters con-
taining the EGR-1 consensus sequence (34). The
EGR-1 consensus is found upstreamofmany transcriptional
start sites, leading to the identification of a number
of promoters that bind in vitro -translated WT1 and
are repressed in transient transfection assay. Haber
and coworkers transfected the four wild type WT1
isoforms into RM1 human anaplasia of the kidney
cell line, a variant form of Wilms’tumor, inocu-
lated into nude mice and observed that each isoform
independently suppressed the emergence of colo-
ny formation (35). Subsequently, they found that
stable transfection of WT1 into RM1 cells results
in induction of endogenous IGF-2 but not of other
previously postulated WT1 target genes (34).
WT1 is expressed only in specific types of cells,
which is a major difference from RB or p53 (36).
The pattern of normal WT1 expression has pro-
vided important clues to the function of WT1
during differentiation. The WT1 protein is mainly
expressed in developing kidney, testis, and ovary,
indicating that it is involved in the differentiation
of genitourinary tissues. Other organs expressing
the protein are spleen and the methothelial cells of
heart, lung and abdomen (36-38). In the kidney,
WT1 is expressed only in condensing blastemic
cells, renal vesicles, and glomerular epithelium, all
thought to be sites of origin of Wilms’tumor.
RenalWT1 expression peaks around the time of birth
and then rapidly declines as the organ matures
(37, 38). In contrast to its transient expression in
the developing kidney, WT1 is expressed continu-
ously in methothelial cells, sertoli cells of testis,
and granulosa cells of the ovary (39). The critical
developmental role of WT1 is evident in the severe
genitourinary and methothelial abnormalities of
mice whose WT1 alleles have been deleted. WT1
knock-out mice die before birth with failure of
kidney and gonadal development in addition to
hypoplasia of the heart and lungs (40).
The WT1 protein is present in normal breast
tissue and appears to be developmentally regu-
lated in that a high percentage of breast tumor
cells express little or no WT1 protein. It is known
that breast tumor growth is controlled by the
genes encoding components of the IGF and TGF-β
signaling system and, recently, altered expression
ofWT1 in breast cancer was also reported (41).
WT2 at 11p15
The second Wilms’tumor gene was identified at
chromosome locus 11p15 and designated WT2
(42, 43). This locus is linked to the Beckwith-Wiedemann
syndrome (BWS), showing manifestations such as
visceromegary, macroglossia, or hemihypertrophy
in some patients (43, 44). p57 was recently identi-
fied as a cyclin-dependent kinase (CDK) inhibitor,
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which is found to have the strongest tumor sup-
pressor activity among the genes of the p21 family
(45, 46). As shown in Figure 2, like related family
members such as p21 and p27 , p57 binds to sev-
eral G1-cyclin/CDK complexes and arrests the cell
cycle at the G1 phase (47). Human p57 is found at
chromosome locus 11p15.5, a region implicated in
the etiology of embryonal tumors including Wilms’
tumor and BWS. Frequent loss of 11p15.5 in Wilms’
tumor indicates that WT2 is located in this region
(45, 48).
Role in rhabdoid tumor of the kidney
The author established two cell lines of rhabdoid
tumor of the kidney (RTK), SWT-1 and SWT-2, as
shown in Figure 3 (49). RTK was once proposed
to be a variant of Wilms’tumor and subsequently
segregated from an unfavorable type of sarcomatous
renal tumor that was grouped with clear cell sar-
coma (CCSK) and anaplasia of the kidney (50-53).
It is well known that RTK has a much poorer
prognosis than Wilms’tumor (50, 52, 53). In an
attempt to identify the etiology of RTK, the mRNA
expression of genes including WT1, p57, IGF-2,
p53, N-myc, and c-myc was tested using reverse
transcriptase-polymerase chain reaction (RT-PCR)
in the two cell lines. The expressions were com-
pared with those in a biopsied kidney tissue and a
normal mesangeal cell line, MCP-3. Coinciding
with the karyotype of SWT-2 cell lines, del 11p13
as shown in Figure 4, no mRNA expression of
Figure 2. The relation between the proteins that regulate cell
cycle progression.
Figure 3. Ultrastructure of SWT-1 and SWT-2. Intermediate filaments characteristic for the rhabdoid tumor can be seen around the
perinuclear field.
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WT1 was found. Interestingly, SWT-1, which showed
a normal karyotype at least on the G-banding analy-
sis, also lacked the WT1 expression as shown in
Figure 5. In addition, SWT-2 lacked the expression
of two genes, p57 and IGF-2, while SWT-1 ex-
pressed them. Both N-myc and c-myc expression
was detected in the two cell lines (data not shown).
These results strongly suggest that WT1 is in-
volved in the etiology of RTK. However, transient
transfection of WT1 did not reduce colony forma-
tion in the other RTK cell line, SM 2 (35). The eti-
ology of RTK may need other genetic abnormalities
in addition to WT1 . The presence of p57 mRNA in
SWT-1 implies that WT2 is not involved in the
etiology of this disease.
Other functions of WT1
cDNA constructs encoding the four human WT1
splice variants caused programmed cell death, which
was associated with a reduced synthesis of EGF-R
in human osteosarcoma cell lines, U2OS and Saos-2
(54). The effect of this assay was independent of
the presence of the p53 gene. However, the nature
of the recipient cells themselves is an important
factor in these transient transfection studies. WT1
and p53 proteins are associated in vivo and transfection
ofWT1 into cells deleted of the p53 gene results in
transcriptional activation, an effect that is sup-
pressed by the reinduction of wild-type p53 (18).
WT1 was transiently transfected into the p53-negative
Hep3B and the p53-positive Hep2G hepatoma cell
lines, resulting in the induction of apoptosis in both
cell lines by the wild type splice variant, whereas
the WT1 (+KTS) isoform did not induce apoptosis
(55). This result is independent of the effect of
p53, which seems to contradict a previous publica-
tion in which the expression of theWT1 (-/-) isoform
was reported to suppress p53-induced apoptosis
in both U2OS and E1A-transformed baby rat kidney
(18). Thus, the observation that the effect of the
WT1 isoforms is cell type dependent may explain
these discrepancies. Subsequently, it was demonstrated
that inducible expression of WT1 in osteosarcoma
cells triggers programmed cell death through an
effect that is associated with transcriptional repres-
sion of endogenous EGFR. This WT1 mediated
apoptosis was preceded by induction of the CDK
inhibitor p21, associated with G1 phase arrest
(56).
Microinjection of the WT1 cDNA into quiescent
cells or cells in early to mid G1 phase blocked
serum-induced cell cycle progression into S phase,
from which inhibition of the activity of cyclin/CDK
complexes may be involved inmediating theWT1-induced
cell cycle block (57).
Mutation of WT1
Mutations in the WT1 gene underlie 5 % to 10 %
of cases of sporadic Wilms’tumor (58). Athough
the majority follow Knudson’s two-hit hypothesis
for tumor suppressor genes, it is now clear that a
substantial minority (～30 %) of Wilms’tumors
retain one normal WT1 allele, suggesting that in
some cases, heterozygous mutation is sufficient
for tumorigenesis. Five different types of mutations
Figure 4. Structure of the short arm of chromosome 11 and
the karyotype of SWT-2. SWT-2 shows del 11p13. The WT1 and
aniridia gene of Pax6 are located at band 11p13, and p57 and
IGF-2 are located at band 11p15.5.
Figure 5. No WT1 mRNA expression in two RTK cell lines.
Neither RTK cell line expresses WT1 whereas the biopsied
kidney sample (BK) and normal mesangeal cell line (MCP-3)
show weakly positive expression.
M. Hirose. The role of Wilms’ tumor genes１３４
are commonly found in Wilms’tumors : large dele-
tions of part of the gene, nonsense or frameshift
mutations affecting amino acids in the zinc fingers
critical for DNA binding, missense mutations affecting
the putative activation or repression domains, and
mutations preventing correct soliciting. Approxi-
mately 75 % of theWT1mutations found in sporadic
Wilms’tumor produce a truncated protein, whereas
missense mutations in the zinc finger region pre-
dominate in Denys-Drash syndrome (DDS)(58).
Wilms’tumor patients have an increased frequen-
cy of leukemias as second primary tumors, some
of which may be due to WT1 mutation (59). The
biological significance of DNA binding and
transcriptional regulation by WT1 is underscored
by the finding of small deletions and point mutations
in the WT1 zinc-fingers that abolish DNA binding
in a number of Wilms’tumors, especially in tumors
associated with the DDS (60). Consequently, the
ability of the mutant WT1 allele, containing an
in-frame deletion within the DNA-binding domain,
to transform baby rat kidney was tested. The mutant
WT1 gene was found to cooperate with the adenoviral
E1A gene in transforming baby rat kidney cells,
whereas the wild-type WT1 gene in all of its
alternatively spliced forms neither suppressed
E1A-induced focus formation in soft agar nor
cooperated with E1A (61).
Expression in hemopoetic cells
The WT1 gene is strongly over-expressed in
leukemic blasts compared with immature hematopoetic
progenitors with an increase in its expression levels at
relapse and an inverse correlation between its
expression levels and prognosis, making it a novel
marker for leukemia cells. The poor prognosis and
the higher level of WT1 gene expression are linked
in patients with leukemia. Thus, it was supposed
that the aberrant over-expression of WT1 contrib-
uted to the pathogenesis of AML (62, 63). In
addition, WT1 was shown to be useful in the
monitoring of minimal residual disease in patients
with hematologic malignancy. However, a conse-
quential result that normal CD34 positive stem
cells as well as acute myeloid leukemia cells equal-
ly expressWT1 mRNA was obtained (64).
It was reported that K562 cells down regulate
WT1mRNA during induced erythroid andmegakaryocytic
differentiation (65). The same phenomenon was
observed in HL60 cells, suggesting that sustained
high levels of WT1 are incompatible with differen-
tiation (66). Likewise, the expression of WT1
inversely correlated with the differentiation level
of acute leukemias (67). WT1 antisense oligomers
inhibit the cell growth of both leukemic cell lines
and fresh leukemic blasts from patients with acute
leukemia or chronic myeloid leukemia, indicating
that the WT1 protein may be important for the
sustained proliferation of leukemia cells (68).
Contrary to these findings, the monoblastic cell
line, U937, constitutively expressing either of the
isoforms, (-KTS) or (+KTS), did not respond to
differentiation induction by retinoic acid or vitamin
D3, whereas the cell line unable to express this
gene responded to these substances (69). A recent
result indicated that WT1 expression competes
with the differentiation-inducing signal mediated
by G-CSF receptor and constitutively activated
Stat3, resulting in the blocking of differentiation
and subsequent proliferation (70). WT1 mutation
is associated with a failure to achieve complete
remission and a lower survival rate in AML, con-
firming that WT1 mutations underlie a similar pro-
portion of cases of AML to that seen in Wilms’
tumors and its normal role in hemopoesis is at a
very early progenitor stage (71).
Relation between WT1 and multidrug re-
sistance (MDR)
The drug resistance that is a major obstacle to
cancer treatment develops at the initial stage of
the therapy or during chemotherapy after relapse
(72). p170-kd permeability-related glycoprotein
(P-GP) encoded by the mdr-1 gene has ATPase
activity which reduces the intracellular drug accu-
mulation by increasing the efflux of anti-cancer
drugs from cells (73, 74). p190-kd multidrug
resistance-associated protein (MRP) encoded by
the mrp gene is a member of the ATP-binding
cassette super family of membrane transporter
proteins that displays minor homology to P-GP
(75). It is known that both P-GP and MRP are
expressed in normal peripheral blood lympho-
cytes (PBL), monocytes, and granulocytes as well
as cells of hematologic disease. However, the
spectrum of cells expressing P-GP is narrow as
compared with those expressing MRP, which
exists in a wider spectrum of cells or tissues than
P-GP (76-79). In recent years, a 110-kd lung
resistance-related protein (LRP) has been found
１３５The Journal of Medical Investigation Vol.46 1999
(80), which is reported to be expressed in monocytes
among the bone marrow cells (81).
In an attempt to understand the cause of the
poor prognosis of leukemia patients whose leuke-
mia cells expressed a high level of WT1 , the author
investigated the relation betweenWT1 and multidrug
resistance (MDR). The expression level of the
WT1 gene in human hemopoetic cells such as pe-
ripheral blood lymphocytes (PBL), interleukin-2
activated lymphocytes (IL-2L), the lymphoblastoid
cell lines immortalized by EBV (EBV-LCL), and
the cultured cell lines derived from human hema-
tologic malignancies was compared with that of
mdr-1, mrp, and lrp in Table 2. Positive expres-
sions of MDR-related genes as above were de-
tected in all PBL, IL-2L, and EBV-LCL, while the
WT-1 expression was found in immortalized cell
lines such as EBV-LCL and hematologic malignancies.
However, the results using normal cells or wild
type cell lines did not demonstrate any positive
correlation between MDR-related genes and WT1 .
Subsequently, the author tested the expression of
WT1 in vincristine (VCR) resistant cells. As shown
in Figure 6, in three VCR-resistant cells that in-
duced mdr-1, WT1 correlated with the progres-
sion of drug resistance and the increase of mdr-1
expression. The disappearance of p53 may suggest
a linkage with mdr-1 and WT1. Thus, it became
obvious that the high level of WT1 expression is a
promising diagnostic marker for drug resistance
(82). Another study reported the relation between
WT1 mutations and chemoresistance (81). Although
it is apparent that the WT1 gene is linked to the
poor prognosis that is caused by the chemoresistance
in hematologic malignancies, little is known of the
role of WT1 . The role of WT1 in the hematologic
malignancies merits further investigation.
Figure 6. The mRNA expression of WT1 and MDR-related
genes in vincristine resistant hematologic cell lines. The PCR
was initiated with 50 ng of cDNA and every PCR went through
28 cycles because the products increased linearly until 30 PCR
cycles. Products were analyzed using NIH image.
Table 2 . Expression of MDR-related genes and WT1
Lineage Cell lines Origin mdr-1 mrp lrp WT-1
PBL
T-cell
B-cell
Myeloid
nT, nB
T-cell
B-cell
PBL
IL-2L
EBV-LCL
K-562
KOPM-28
HEL
P39/tsu
ML-1
PL-21
HL-60
THP-1
P31/fuj
CMK
EoLE5
P30/ohk
Reh
KOPN-1
KM-3
Nalm-6
P12/ich
CCRF-CEM
RPMI-8402
MOLT-3
MOLT-4F
HPB-ALL
ATL-1K
MT-2
SKW-3
Raji
P3HR-1
Daudi
BALL-1
BL-TH
P32/ish
A3/kaw
A4/fuk
U-266
PBL
PBL
PBL
CML
CML
EL
MDS
AML
APL
APL
AMoL
AMoL
MegL
EoL
cALL
cALL
cALL
cALL
cALL
T-ALL
T-ALL
T-ALL
T-ALL
T-ALL
T-ALL
ATL
ATL
T-CLL
Afn, BL
Afn, BL
Afn, BL
B-ALL
Jpn, BL
Jpn, BL
Imbl
Imbl
MM
2+
2+
2+
2+
2+
2+
2+
+
2+
w
+
+
+
2+
w
+
+
-
+
-
-
-
-
-
-
+
-
-
-
-
-
-
-
-
-
-
-
-
-
+
-
-
-
-
-
-
-
+
-
-
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
w
2+
2+
w
+
+
2+
2+
+
w
2+
+
+
2+
+
w
+
2+
2+
2+
2+
2+
2+
+
2+
+
2+
2+
w
2+
w
w
+
2+
2+
2+
2+
2+
+
1+
2+
2+
2+
2+
2+
2+
2+
1+
2+
1+
1+
2+
2+
2+
2+
w
-
1+
2+
2+
2+
2+
2+
2+
+
1+
2+
2+
2+
2+
2+
1+
2+
w
2+
1+
w
1+
2+
2+
-
-
-
-
-
-
-
1+
2+
-
-
-
-
-
-
-
-
-
+
+
+
w
2+
+
+
+
-
w
2+
2+
+
+
2+
2+
+
2+
+
-
+
+
2+
2+
+
2+
2+
+
2+
-
-
2+
w
w
2+
-
-
-
-
2+
w
The level of expression was analyzed using NIH image and the
positive expression was divided into three levels by a proper
criterion : -, negative expression ; positive expression was de-
scribed in the order of w<1+<2+.
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